Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Marwan Fakih


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


M.G. Fakih1, D. Wang2, W. Harb3, L. Rosen4, D. Mahadevan5, J.D. Berlin6, P. Basciano7, R. Brown8, O. Arogundade9, C. Cox10, G. Di Genova10, D. Krige10, H. McElwaine-Johnn9

Author affiliations

  • 1 Medical Oncology: Colorectal And Gastrointestinal Cancers, City of Hope National Medical Center, 91010 - Duarte/US
  • 2 Medical Oncology, Henry Ford Cancer Institute, 48202 - Detroit/US
  • 3 Clinical, Horizon Oncology Center, 47905 - Lafayette/US
  • 4 Medical Oncology, UCLA Medical Center, Santa Monica/US
  • 5 Division Of Hematology Oncology, The University of Arizona Cancer Center, 85719 - Tucson/US
  • 6 Oncology, Vanderbilt-Ingram Cancer Center, 37232 - Nashville/US
  • 7 Clinial Development, Bristol Myers Squibb, Prinecton/US
  • 8 Project Management, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB
  • 9 Clinial Development, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB
  • 10 Clinical Assays, PsiOxus Therapeutics Ltd, OX14 3YS - Abingdon/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2518


Enadenotucirev (EnAd) is a tumor-selective chimeric Ad11/Ad3 group B oncolytic adenovirus. Following IV dosing of EnAd, viral delivery has been shown in various carcinomas together with CD8+ T-cells. These data provide a rationale for combination of EnAd with nivolumab (anti-PD-1).


EnAd was escalated in patients with metastatic epithelial tumors in a 3 + 3 design. Subjects received increasing dose levels and/or cycles of EnAd followed by up to 8 cycles of nivolumab. The primary objective of the dose escalation phase was to evaluate safety and recommend a dose for expansion. Secondary endpoints include ORR and OS.


31 patients with metastatic colorectal cancer (mCRC), with median 4 prior lines of therapy, were treated. Of these, 22 are confirmed MSS. EnAd dosing ranged between 1x1012 and 3x1012 virus particles infused IV 3 times weekly for one or two weeks, followed by nivolumab. Flu-like symptoms were reported in the majority of patients following EnAd administration. Adverse events of infusion reaction and hypoxia meeting DLT criteria were reported on C2D1 administration of EnAd requiring increased prophylaxis. Grade 4 acute renal injury was reported in one subject, with renal biopsy showing membranoproliferative glomerulonephritis (GN) indicative of immune complex deposition. Additional monitoring revealed changes suggestive of post-infectious GN in ∼25% of patients after 3-4 weeks of EnAd dosing. These were asymptomatic and resolved without treatment. Kinetics, cytokines and anti-drug antibody responses were consistent with known profiles for both agents. As of 03May2019, median OS is reported as 12.6 mo and median PFS is 2.8 mo. There were no objective responses, but PD markers in 6/8 matched biopsy samples show evidence of increased CD8 T cell infiltration and upregulation of markers of T cell activation. Stable disease exceeding 4 mo was seen in 6/31 (4/22 MSS).


The combination of EnAd and nivolumab has a manageable toxicity profile supporting further investigation in study expansion. Favourable OS outcome in a highly refractory CRC population was noted and may suggest delayed immune antitumor activity in this population.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

PsiOxus Therapeutics Ltd.


PsiOxus Therapeutics Ltd; Bristol-Myers Squibb.


P. Basciano: Full / Part-time employment: Bristol-Myers Squibb. R. Brown: Shareholder / Stockholder / Stock options, Full / Part-time employment: PsiOxus Therapeutics Ltds. O. Arogundade: Full / Part-time employment: PsiOxus Therapeutics Ltds. C. Cox: Full / Part-time employment: PsiOxus Therapeutics Ltds. G. Di Genova: Full / Part-time employment: PsiOxus Therapeutics Ltds. D. Krige: Full / Part-time employment: PsiOxus Therapeutics Ltds. H. McElwaine-Johnn: Leadership role, Shareholder / Stockholder / Stock options, Full / Part-time employment: PsiOxus Therapeutics Ltds. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.